Kraig Biocraft Laboratories Inc (KBLB)

[Rocket929]

My 2 cents...
- A company like this (pre-revenue) needs money to scale up. Increasing outstanding shares to get more $$ harms the investors. So they don’t want to and choose uplisting faster as a better option.
- To scale up we do need more $$. The pace of scaling up seems to have quickened. So we may be in a forced position to uplist quicker than expected, thus necessitating the option to R/S (which scares folks enamored with extremely high numbers of cheap shares enjoying their huge gains on mere penny increases)
- uplisting allows for institutional investors allowing for additional funding without significant negative impact on shareholders
- if R/S occurs, it’s a necessary evil.
- most R/S that occur in companies don’t occur for these reasons, so it’s not a good comparison
- I’ve been asking about timing in several posts. I believe the timing may be due to pressure from partners and institutional investors who want to get moving more quickly.
- I’m hopeful the pps increases on good news to where it won’t be needed, otherwise praying for the minimum R/S
Not convinced we still won’t see the big payday. GLTA